Asciminib Monotherapy for T315I-Mutated Chronic-Phase Chronic Myeloid Leukemia After ≥1 Prior TKI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Leukemia 2024 May 16;[EPub Ahead of Print], JE Cortes, K Sasaki, DW Kim, TP Hughes, G Etienne, MJ Mauro, A Hochhaus, F Lang, MC Heinrich, M Breccia, M Deininger, YT Goh, JJWM Janssen, M Talpaz, VGG de Soria, P le Coutre, DJ DeAngelo, A Damon, S Cacciatore, F Polydoros, N Agrawal, D ReaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.